Research programme: inflammation therapy - Amylin Pharmaceuticals/BioSeek
Latest Information Update: 15 Jun 2010
At a glance
- Originator Amylin Pharmaceuticals
- Developer BioSeek
- Class Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Inflammation